Estimate of Burden: Public reporting burden for this collection of information is estimated to average 0.27 hours per response.

Respondents: Producers, handlers, processors, dehydrators, cooperatives, manufacturers, importers, and public members.

Estimated Number of Respondents: 3,172.

Estimated Total Annual of Responses: 18,033 (rounded).

Estimated Number of Responses per Respondent: 5.69.

Estimated Number of Recordkeeping hours: 476 hours.

Estimated Total Annual Burden on Respondents: 4,946.04 hours (rounded).

Comments are invited on: (1) Whether this collection of information is necessary for the proper performance of the functions of the agency, including whether the information has practical utility; (2) the accuracy of the agency's estimate of the burden of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information collected; and (4) ways to minimize the burden of the collection of information on those who respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Erin Morris,

Administrator, Agricultural Marketing Service.

[FR Doc. 2026–19420 Filed 9–22–26; 8:45 am]

BILLING CODE 3410–02–P

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

[Docket No. 260918–0006]

RIN 0694–XC154

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

AGENCY: Bureau of Industry and Security, Office of Strategic Industries and Economic Security, U.S. Department of Commerce.

ACTION: Notice.

SUMMARY: This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an *ad valorem* tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, ''Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,'' (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. Proclamation 11020 states that such products and associated ingredients receive the Section 232 zero tariff rate if they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement or if they meet an urgent U.S. health need. This notice also includes procedures for the public to submit information for the Department of Commerce's (Commerce) approval to determine if imports of the pharmaceutical products and associated ingredients meet an urgent U.S. health need. This notice also issues five technical corrections to Annex I and one technical correction to Annex IV of the Proclamation.

DATES: Submission of information will be received on an ongoing basis starting September 23, 2026.

ADDRESSES: Information requesting Commerce's approval for pharmaceutical products that meet an urgent U.S. health need must be submitted electronically to: *pharma232@bis.doc.gov.*

FOR FURTHER INFORMATION CONTACT: Stephen Astle, Director, Defense Industrial Base Division, Office of Strategic Industries and Economic Security, Bureau of Industry and Security, U.S. Department of Commerce (202) 482–2533, *pharma232@bis.doc.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

On April 2, 2026 the President issued Proclamation 11020, ''Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,'' (91 FR 18183) (Proclamation 11020) concurring with the Secretary of Commerce's (Secretary) finding that pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances that threaten to impair the national security of the United States and imposing tariffs to adjust imports of such products pursuant to section 232 of the Trade Expansion Act of 1962, as amended (19 U.S.C. 1862) (Section 232). Proclamation 11020 imposed a 100 percent *ad valorem* tariff on certain imports of patented pharmaceuticals and associated pharmaceutical ingredients, effective July 31, 2026 for the companies listed in Annex III of Proclamation 11020, and September 29, 2026 for all other companies. Different rates apply to patented pharmaceutical products and associated ingredients from certain jurisdictions and from companies with Commerce-approved onshoring agreements (Bureau of Industry and Security, ''Procedures To Apply for Company-Specific Onshoring Agreements To Obtain Tariff Adjustments for Pharmaceuticals and Pharmaceutical Ingredients Under Proclamation 11020'' (92 FR 26989; May 13, 2026)). At this time, Section 232 Pharmaceutical Tariffs do not apply to generic pharmaceutical products and associated ingredients.

In clause 3(d) of Proclamation 11020, the President directed an *ad valorem* tariff rate of zero to apply for pharmaceuticals and associated ingredients that are designated as orphan pursuant to the Orphan Drug Act (21 U.S.C. 360aa *et seq.*) and its implementing regulations; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; or other specialty pharmaceutical products to be identified by the Secretary, as well as pharmaceutical products for animal health, provided that the Secretary, in consultation with the United States Trade Representative (USTR) and the Secretary of Health and Human Services (HHS), determines that: (1) they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement as referenced in Executive Order 14346, ''Modifying the Scope of Reciprocal Tariffs and Establishing Procedures for Implementing Trade and Security Agreements'' of September 5, 2025 (90 FR 43737) (Executive Order 14346), or (2) they meet an urgent U.S. health need.

Proclamation 11020 directs the Secretary, in consultation with the Chair of the United States International Trade Commission and the Commissioner of U.S. Customs and Border Protection (CBP), to determine whether any modifications to the HTSUS or other

administrative measures are necessary to effectuate or implement the Proclamation or any actions taken pursuant to the Proclamation. Any changes are to be published in a notice in the **Federal Register**.

II. Definitions of Pharmaceutical Products Listed in Clause 3(d) of Proclamation 11020

Commerce consulted with the Food and Drug Administration (FDA) and U.S. Department of Agriculture Center for Veterinary Biologics to provide the following definitions of the pharmaceutical products listed in clause 3(d) of Proclamation 11020. The definitions are solely for purposes of determining eligibility of the *ad valorem* tariff rate of zero pursuant to Proclamation 11020 and should not be construed as binding guidance for any other purpose unrelated to Proclamation 11020. This list of definitions covers imports of investigational drugs as well as FDA-approved or FDA-authorized drugs. Commerce reserves the right to modify these definitions in the future.

- *Drug where all approved or licensed indications are designated as orphan:* A drug or biological product that is designated under Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb) for one or more rare diseases or conditions, and for which all approved indications under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) of this title or licensed under Section 351 of the Public Health Service Act (42 U.S.C. 262), are for one or more such rare diseases or conditions.
- *Nuclear medicine:* A drug that meets the definition of ''radioactive drug'' in 21 CFR 310.3(n) or a biological product that meets the definition of ''radioactive biological product'' as defined in 21 CFR 600.3(ee).
  - *21 CFR 301.3(n):* Radioactive drug means any substance defined as a drug in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act which exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any nonradioactive reagent kit or nuclide generator which is intended to be used in the preparation of any such substance but does not include drugs such as carbon-containing compounds or potassium-containing salts which contain trace quantities of naturally occurring radionuclides. The term 'radioactive drug' includes a 'radioactive biological product' as defined in 21 CFR 600.3(ee).
  - *21 CFR 600.3(ee):* Radioactive biological product means a biological product which is labeled with a radionuclide or intended solely to be labeled with a radionuclide.
- *Plasma derived therapy:* A biological product that is derived from human whole blood or plasma. (42 U.S.C. 1320f-1(e)(3)(C)).
- *Fertility drug:* A drug or biological product for the treatment of infertility, including drugs approved for the treatment of ovulatory dysfunction in women desiring pregnancy.
- *Cell therapy product:* A biological product that is a cellular immunotherapy, cellular cancer vaccine, or other type of autologous or allogeneic cellular product approved for one or more therapeutic indications, including hematopoietic stem cell products and adult and embryonic stem cell products.
- *Gene therapy product:* A biological product that is intended to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use.
- *Antibody drug conjugates:* A combination product composed of a small-molecule drug (payload) and an antibody or antibody fragment, conjugated together by a chemical linker.
- *Medical countermeasures related to chemical, biological, radiological, and nuclear threats:* A drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)), or a biological product as defined in section 351(i) of the Public Health Service Act (42 U.S.C. 262(i)), that is for use to diagnose, prevent, or treat diseases or conditions caused by chemical, biological, radiological, or nuclear threat (CBRN) agents, including emerging infectious diseases, and include qualified countermeasures as defined in section 319F–(a)(2)(A) of the Public Health Service Act (42 U.S.C. 247d–6a), qualified pandemic or epidemic products as defined in section 319F–3(i)(7) of the Public Health Service Act (42 U.S.C. 247d–6d); and security countermeasures as defined in section 319F–2(c)(1)(B) of the Public Health Service Act (42 U.S.C. 247d–6b).
- *Animal Healthcare Products:* Animal healthcare products include articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals; articles (other than food) intended to affect the structure or any function of an animal's body; or articles intended for use as components of such products. The definition includes veterinary pharmaceuticals intended to manage diseases, conditions, or injuries in animals but does not include devices or combination products for animals. Animal healthcare products also include biologics (vaccines, bacterins, and diagnostic products) used in the treatment of diseases in animals and is regulated by USDA–CVB (Center for Veterinary Biologics).

III. List of Eligible Jurisdictions

The following jurisdictions are eligible for the tariff adjustment described in clause 3(d) of Proclamation 11020: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, United Kingdom, and Vietnam. Changes to the list of eligible jurisdictions may be published in a future notice.

IV. Procedures for Requesting Commerce Approval for Pharmaceuticals That Meet an Urgent U.S. Health Need

Companies can request approval from Commerce for imports of pharmaceutical products listed in clause 3(d) of Proclamation 11020 or other specialty products if such imports meet an urgent U.S. health need. Companies should email the Bureau of Industry and Security (BIS) at *pharma232@bis.doc.gov* with the following information for each requested product or ingredient:

1. *Section 1—Organization Information:* Full legal name and address of the company. The name, title, and contact information of the authorized representative submitting the application should also be included.

2. *Section 2—Tariff Adjustment for Urgent U.S. Health Need:* Companies should provide the following information, with respect to the product for which they request preferential treatment to meet an urgent health need in the United States. Only one specific product may be submitted per application form.

- HTSUS Classification (10-digit, if possible)
- Advertised name and brand of product or Investigational New Drug Application number, as applicable, as well as active ingredient (or combination of active ingredients)
- Indicate the category of the requested product: orphan, nuclear medicine, plasma derived therapies, fertility drugs, cell therapy product, gene therapy product, antibody drug conjugates, medical countermeasures related to CBRN threats, or animal health
- Country of origin and country of export of products imported under each HTSUS Classification

- Name and IOR Number of Importer(s) of Record
- Name and address of manufacturer

3. *Section 3—Rationale for why the import meets an urgent U.S. health need:* The rationale can include information such as the type of disease the product treats and an assessment of alternative therapies or lack of alternative therapies for the type of disease the product treats, the number of U.S. patients that use the product, and whether or not the product is available in other jurisdictions. The requests for approval should only be for patented pharmaceutical products and associated ingredients that are covered under the HTSUS codes listed in Annex I of Proclamation 11020. Submission of information will be received on an ongoing basis.

Review and Approval Process

Commerce may request supplemental documentation or clarification. As directed in Proclamation 11020, Commerce will consult with the USTR and HHS to determine if the requested product meets an urgent U.S. health need. Commerce will make an individual, fact-specific, company-specific decision for each request. Companies will be notified in writing of Commerce's decision. Relevant information from the request will be transmitted by Commerce to CBP. CBP will administer the tariff adjustment at the time of entry summary filing and may request additional documentation to validate entries.

Confidentiality

Commerce will protect the confidentiality of all information submitted by companies requesting approval of specialty pharmaceutical product imports that meet an urgent U.S. health need.

Commerce will protect the confidentiality of confidential, trade secret, and/or proprietary information excluding information in the public domain (''confidential information'') provided by the Drug Manufacturer to the fullest extent allowed by law. For example, subject to applicable laws, such information would be protected from disclosure by the Trade Secrets Act (18 U.S.C. 1905) and under Exemptions 3 and/or 4 of the Freedom of Information Act (''FOIA'') (5 U.S.C. 552(b)(3), (4)). Commerce shall limit dissemination of a Drug Manufacturer's confidential information to those persons within its organization, USTR, and other executive branch agencies and entities who have a need to know such information to fulfill the purpose of determining whether imports of requested specialty pharmaceutical products meet an urgent U.S. health need.

V. Technical Corrections to the HTSUS

This notice and its accompanying annexes provide for five technical corrections to Annex I and one technical correction to Annex IV of Proclamation 11020.

Annex I Technical Corrections: The first correction amends the definition of ''generic pharmaceutical articles'' in subdivision (c)(iii) with respect to heading 9903.04.67. The definition of ''generic pharmaceutical articles'' is modified to specifically include ''unpatented animal health products.''

The second correction includes a new heading in Chapter 99 of the HTSUS with an ad valorem tariff rate of zero. Filers should use this new heading for pharmaceutical products and associated ingredients that are imported under HTSUS Classifications listed in subpart (c) of U.S. note 40 which are solely intended for clinical trials, research and development, or other non-commercial applications.

The third correction amends the definition of ''pharmaceutical articles'' in subdivision (c)(i) to clarify that this definition only encompasses finished pharmaceutical products, their active pharmaceutical ingredients, and the key starting materials of said active pharmaceutical ingredients.

The fourth correction amends the text of subdivision (i) with respect to heading 9903.04.69 to clarify that this provision encompasses any pharmaceutical or non-pharmaceutical articles imported under an HTSUS Classification listed in subpart (c) of U.S. note 40 that are not finished pharmaceutical products, their active pharmaceutical ingredients, or the key starting materials of said active pharmaceutical ingredients.

The fifth correction amends Annex I to incorporate recent HTSUS changes made by the Committee for the Statistical Annotation of Tariff Schedules on July 1, 2026. This interagency committee includes representatives from the U.S. International Trade Commission, CBP, and the U.S. Census Bureau.

Annex IV Technical Correction: The technical correction to Annex IV corrects an inconsistency of certain HTSUS Classifications listed in Annex IV that overlap with Annex I. The following HTSUS codes are removed from Annex IV: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00, and 3004.49.00.

VI. Paperwork Reduction Act

The Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*) provides that an agency generally cannot conduct or sponsor a collection of information, and no person is required to respond to nor be subject to a penalty for failure to comply with a collection of information, unless that collection has obtained Office of Management and Budget (OMB) approval and displays a currently valid OMB Control Number.

In Proclamation 11020, the President determined it was necessary and appropriate to apply an *ad valorem* tariff rate of zero for the following specialty pharmaceutical products and associated ingredients when certain conditions are met pursuant to clause 3(d) of Proclamation 11020: drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. The President authorized the Secretary of Commerce, in consultation with the USTR and the Secretary of HHS, to determine that: (1) they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement as referenced in Executive Order 14346; or (2) they meet an urgent United States health need.

Because the Proclamation requires timely implementation of the specialty pharmaceutical tariff adjustments to further U.S. economic and national security interests by making pharmaceuticals more accessible and affordable in the United States, BIS cannot reasonably comply with the normal clearance procedures. Delaying this collection would impede the ability of companies to request approval for imports of specialty pharmaceutical products that meet an urgent United States health need and compromise the effectiveness of the Proclamation's implementation. The Department has determined the following conditions have been met:

a. The collection of information is needed prior to the expiration of time periods normally associated with a routine submission for review under the provisions of the Paperwork Reduction Act in view of Proclamation 11020, *https://www.federalregister.gov/documents/2026/04/09/2026-06956/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states.* (5 CFR 1320.13(a)(1)(i)).

b. The collection of information is essential to the mission of the Department, in particular to allow companies seeking to obtain the zero *ad valorem* tariff by requesting approval for imports of specialty pharmaceutical products that meet an urgent United States health need to effectuate the terms outlined by Proclamation 11020 (5 CFR 1320.13(a)(1)(ii)). These collection requirements include a description of the specialty pharmaceutical product, country of origin information, and rationale for why the import meets an urgent United States health need. The information must be submitted in electronic form via email to the BIS Section 232 Pharmaceuticals Investigation Inbox (*pharma232@bis.doc.gov*). Requests for approval of imports that meet an urgent United States health need may be submitted at any time following publication of this FRN publication and all submissions are entirely voluntary on the part of the requesting companies.

c. Public harm is reasonably likely to result if BIS were to follow the normal clearance procedures before issuing this information collection (5 CFR 1320.13(a)(2)(i)). BIS needs time to receive and evaluate requests for specialty pharmaceutical products that meet an urgent United States health need before September 29, 2026, when the Section 232 tariffs for most companies will become effective. A delay in Commerce's ability to begin immediate information collection from companies seeking approval to import specialty pharmaceutical products that meet an urgent United States health need and inability to issue decisions before the 100 percent tariff rate is in effect creates uncertainty for companies' understanding of their tariff liability and could also cause supply chain disruptions.

For the reasons stated above, BIS has requested, and OMB has granted, a new information collection for this rule under OMB control number 0694–0150 with the title *Section 232 National Security Adjustments to Imports of Specialty Pharmaceuticals.* All materials for the currently approved collection can be accessed at *www.reginfo.gov*. Separately, BIS will be publishing a 60 day notice to take comment on the emergency collection.

Jessica Curyto,

Deputy Assistant Secretary for Technology Security.

Annex I

Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on September 29, 2026, subchapter III of chapter 99 of the Harmonized Tariff Schedule of the United States (''HTSUS'') is modified as follows:

1. U.S. note 40 is modified:

a. In subdivision (a), by deleting ''9903.04.60–9903.04.69'' and inserting ''9903.04.60–9903.04.70'' in lieu thereof;

b. In subdivision (c), by deleting the enumerated HTSUS provisions and inserting the following in lieu thereof:

''2918.99.3000	2921.49.3800	2921.49.4300	2922.19.0910
2922.19.0990	2922.29.2700	2922.49.2600	2922.50.1400
2922.50.2500	2924.29.6250	2925.29.2000	2928.00.3000
2930.90.9235	2931.90.2200	2932.20.2000	2933.19.3500
2933.19.4500	2933.29.2000	2933.29.4500	2933.39.4100
2933.49.2600	2933.59.2100	2933.59.3600	2933.59.4600
2933.59.5300	2933.59.5900	2933.79.0800	2933.79.8500
2933.99.4600	2933.99.5300	2933.99.5590	2933.99.6100
2933.99.6500	2933.99.7000	2933.99.7500	2933.99.9000
2934.30.2300	2934.30.2700	2934.99.3000	2934.99.4720
2934.99.4730	2934.99.4740	2934.99.4790	2935.90.4800
2935.90.6000	2937.11.0000	2937.12.0000	2937.19.0000
2937.22.0010	2937.22.0090	2937.23.1010	2937.23.1050
2937.23.5010	2937.23.5020	2937.23.5050	2937.29.9040
2937.29.9050	2937.29.9095	2937.50.0000	2937.90.4500
2937.90.9000	2938.90.0000	2939.11.0000	2939.19.2000
2939.19.5000	2941.10.5000	2941.90.1050	2941.90.3030
2941.90.3090	2941.90.5030	2941.90.5090	2942.00.0500
3002.12.0040	3002.13.0010	3002.13.0090	3002.14.0010
3002.14.0090	3002.15.0011	3002.15.0091	3002.41.0000
3002.42.0000	3002.49.0050	3002.51.0000	3002.59.0000
3002.90.1000	3002.90.5220	3002.90.5250	3003.20.0000
3003.31.0000	3003.39.1000	3003.39.5000	3003.49.0000
3003.90.0120	3003.90.0140	3003.90.0180	3003.90.0190
3004.10.1010	3004.10.5010	3004.20.0010	3004.20.0042
3004.20.0058	3004.20.0073	3004.20.0074	3004.20.0078
3004.20.0085	3004.31.0010	3004.31.0090	3004.32.0020
3004.32.0080	3004.39.0010	3004.39.0015	3004.39.0080
3004.41.0000	3004.49.0005	3004.49.0010	3004.49.0020
3004.49.0030	3004.49.0040	3004.49.0050	3004.49.0060
3004.49.0070	3004.50.5005	3004.90.1000	3004.90.9201
3004.90.9206	3004.90.9208	3004.90.9210	3004.90.9211
3004.90.9212	3004.90.9215	3004.90.9216	3004.90.9217
3004.90.9218	3004.90.9226	3004.90.9236	3004.90.9243
3004.90.9246	3004.90.9249	3004.90.9251	3004.90.9252
3004.90.9253	3004.90.9260	3004.90.9263	3004.90.9267
3004.90.9268	3004.90.9270	3004.90.9271	3004.90.9273
3004.90.9276''			

c. In subdivision (c), by deleting item (i) and inserting the following in lieu thereof:

''(i) ''Pharmaceutical articles'' refers to imported articles classifiable in the provisions enumerated in this subdivision that are finished pharmaceutical products or that are active pharmaceutical ingredients (including key starting materials for active pharmaceutical ingredients) classifiable in the provisions enumerated in this subdivision used to make finished pharmaceutical products. Inactive ingredients and excipients are not pharmaceutical articles.'';

d. In subdivision (c)(iii), by deleting the second sentence and inserting the following sentence in lieu thereof:

''A generic pharmaceutical article is an active pharmaceutical ingredient or any component in a finished dosage form product that is used in a drug product or biosimilar biological product approved pursuant to a qualifying application; or a drug product or biosimilar biological product approved or licensed pursuant to a qualifying application; or an unpatented animal health product.''; and

e. By deleting subdivision (i) and inserting the following in lieu thereof:

''(i) Heading 9903.04.69 applies to entries of articles that are classifiable under provisions of the HTSUS enumerated in subdivision (c) of this note that are either: (1) not ''pharmaceutical articles'' as defined in subdivision (c)(i) of this note, or (2) are ''pharmaceutical articles'' but are neither ''patented pharmaceutical articles'' nor ''generic pharmaceutical articles'' as those terms are defined in subdivisions (c)(ii) and (c)(iii) of this note.''

2. The following new heading is inserted in numerical sequence, with the material for the new heading inserted in the columns of the HTSUS labeled ''Heading/Subheading'', ''Article Description'', ''Rates of Duty 1-General'', ''Rates of Duty 1-Special'' and ''Rates of Duty 2'', respectively:

Heading/ subheading	Article description	Rates of duty		
		1		2
		General	Special	
''9903.04.70 ..	Pharmaceutical articles and associated ingredients provided for in subdivision (c) of U.S. note 40 to this subchapter that are solely for use in clinical trials, research and development, or other non-commercial applications.	The duty provided in the applicable subheading + 0%.	The duty provided in the applicable subheading + 0%.	The duty provided in the applicable subheading + 0%''.

Annex II

Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on September 29, 2026, Annex IV of Presidential Proclamation 11020 of April 2, 2026, ''Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,'' (Proclamation 11020) is modified by deleting the enumerated HTSUS provisions and inserting the following in lieu thereof:

''2903.45.1000	2903.51.1000	2903.59.9000	2903.69.9000
2903.78.0000	2903.79.9030	2903.79.9070	2903.89.1500
2903.89.2000	2903.89.7010	2903.89.7090	2903.92.0000
2904.99.4000	2905.29.9000	2905.39.9000	2905.59.1000
2905.59.9000	2906.19.5000	2906.29.6000	2907.29.9000
2908.19.6000	2909.19.1800	2909.20.0000	2909.30.6000
2909.49.1000	2909.49.1500	2909.49.2000	2909.49.6000
2909.50.4010	2909.50.4050	2909.50.4500	2909.50.5000
2912.19.5000	2912.49.2600	2914.19.0000	2914.40.9000
2914.50.3000	2914.50.5000	2914.62.0000	2914.69.2100
2914.69.9000	2914.79.4000	2915.29.3000	2915.39.3100
2915.39.3500	2915.39.4700	2915.39.9000	2915.90.1010
2915.90.1050	2915.90.1400	2915.90.1810	2915.90.1890
2915.90.2000	2915.90.5010	2915.90.5050	2916.19.3000
2916.19.5000	2916.20.5000	2916.31.5000	2916.39.4600
2916.39.7900	2917.13.0030	2917.13.0090	2917.19.1000
2917.19.7020	2917.19.7050	2917.34.0110	2917.34.0150
2917.39.3000	2918.11.5100	2918.13.5000	2918.16.5010
2918.16.5020	2918.16.5090	2918.19.6000	2918.19.9000
2918.22.1000	2918.22.5000	2918.23.3000	2918.23.5000
2918.29.2000	2918.29.6500	2918.29.7500	2918.30.2500
2918.30.3000	2918.30.9000	2918.99.4300	2918.99.4700
2918.99.5000	2919.90.3000	2919.90.5010	2919.90.5050
2920.90.5100	2921.19.1100	2921.29.0010	2921.29.0020
2921.29.0030	2921.29.0055	2921.30.1000	2921.30.5000
2921.42.9000	2921.46.0000	2921.49.4500	2921.49.5000
2921.59.8010	2921.59.8090	2922.11.0000	2922.14.0000
2922.19.2000	2922.19.3300	2922.19.6000	2922.19.7000
2922.19.9000	2922.19.9610	2922.19.9619	2922.19.9690
2922.29.6100	2922.29.8110	2922.29.8190	2922.31.0000
2922.39.2500	2922.39.4500	2922.39.5000	2922.41.0010
2922.41.0090	2922.42.5000	2922.44.0000	2922.49.1000
2922.49.3000	2922.49.3700	2922.49.4910	2922.49.4915
2922.49.4950	2922.49.8000	2922.50.0700	2922.50.1000
2922.50.1100	2922.50.1300	2922.50.1700	2922.50.3500
2922.50.4000	2922.50.5000	2923.10.0000	2923.20.2010
2923.20.2050	2924.11.0000	2924.19.1110	2924.19.1120
2924.19.1130	2924.19.1150	2924.19.8000	2924.21.1600
2924.21.5000	2924.29.0100	2924.29.0300	2924.29.1000
2924.29.2300	2924.29.2600	2924.29.2800	2924.29.3300
2924.29.5700	2924.29.6210	2924.29.6220	2924.29.7100
2924.29.7710	2924.29.7720	2924.29.7730	2924.29.7790
2924.29.8000	2924.29.9500	2925.12.0000	2925.19.4200
2925.19.9100	2925.21.0000	2925.29.6000	2925.29.9000
2926.30.1000	2926.40.0000	2926.90.1400	2926.90.4300
2926.90.4801	2926.90.5010	2926.90.5050	2927.00.4000
2927.00.5000	2928.00.2500	2929.90.2000	2929.90.5015

2929.90.5018	2929.90.5020	2929.90.5030	2929.90.5040
2929.90.5095	2930.20.2010	2930.20.2050	2930.20.9010
2930.20.9020	2930.20.9050	2930.30.6000	2930.90.2900
2930.90.4910	2930.90.4920	2930.90.4950	2930.90.9208
2930.90.9210	2930.90.9212	2930.90.9222	2930.90.9225
2930.90.9231	2930.90.9251	2931.49.0005	2931.49.0008
2931.49.0010	2931.49.0015	2931.49.0020	2931.49.0025
2931.49.0055	2931.49.0080	2931.53.0000	2931.90.9010
2931.90.9021	2931.90.9025	2931.90.9029	2931.90.9030
2931.90.9035	2931.90.9040	2931.90.9052	2932.14.0000
2932.19.5100	2932.20.3000	2932.20.5010	2932.20.5020
2932.20.5030	2932.20.5050	2932.99.6100	2932.99.7000
2932.99.9010	2932.99.9090	2933.11.0000	2933.19.9000
2933.21.0000	2933.29.0500	2933.29.3500	2933.29.4300
2933.29.6000	2933.29.9000	2933.33.0100	2933.34.0000
2933.35.0000	2933.37.0000	2933.39.0800	2933.39.1000
2933.39.2000	2933.39.2100	2933.39.2300	2933.39.2500
2933.39.2700	2933.39.3100	2933.39.6110	2933.39.6120
2933.39.6130	2933.39.6191	2933.39.9200	2933.41.0000
2933.49.0800	2933.49.1000	2933.49.1500	2933.49.1700
2933.49.2000	2933.49.3000	2933.49.6000	2933.49.7000
2933.52.1000	2933.52.9000	2933.53.0000	2933.54.0000
2933.59.1000	2933.59.1500	2933.59.1800	2933.59.2200
2933.59.7000	2933.59.8000	2933.59.8500	2933.59.9500
2933.69.6010	2933.69.6021	2933.69.6030	2933.69.6050
2933.72.0000	2933.79.1500	2933.91.0010	2933.91.0050
2933.99.0100	2933.99.0200	2933.99.0500	2933.99.0600
2933.99.0800	2933.99.1100	2933.99.1200	2933.99.1600
2933.99.1701	2933.99.2200	2933.99.2400	2933.99.2600
2933.99.4200	2933.99.5100	2933.99.5510	2933.99.5520
2933.99.5530	2933.99.5800	2933.99.7900	2933.99.8210
2933.99.8220	2933.99.8290	2933.99.8500	2933.99.8900
2933.99.9701	2934.10.1000	2934.10.2000	2934.10.9000
2934.20.4000	2934.20.8000	2934.30.4300	2934.30.5000
2934.91.0000	2934.92.0000	2934.99.0100	2934.99.0300
2934.99.0500	2934.99.0600	2934.99.0700	2934.99.0800
2934.99.0900	2934.99.1100	2934.99.1200	2934.99.1500
2934.99.1600	2934.99.1800	2934.99.2000	2934.99.3900
2934.99.4400	2934.99.7000	2934.99.9001	2935.50.0000
2935.90.0600	2935.90.1000	2935.90.1300	2935.90.1500
2935.90.2000	2935.90.3000	2935.90.3200	2935.90.3300
2935.90.4200	2935.90.7500	2935.90.9500	2936.21.0000
2936.22.0000	2936.23.0000	2936.24.0100	2936.25.0000
2936.26.0000	2936.27.0000	2936.28.0000	2936.29.1000
2936.29.1610	2936.29.1620	2936.29.1630	2936.29.2000
2936.29.5020	2936.29.5030	2936.29.5050	2936.90.0110
2936.90.0150	2937.21.0010	2937.21.0020	2937.21.0030
2937.21.0040	2937.23.1020	2937.23.2500	2937.29.1000
2937.29.9020	2937.29.9030	2937.90.0500	2937.90.1000
2937.90.2000	2937.90.4000	2938.10.0000	2939.19.1000
2939.20.0010	2939.20.0050	2939.30.0000	2939.41.0000
2939.42.0000	2939.44.0000	2939.45.0000	2939.49.0300
2939.59.0000	2939.62.0000	2939.63.0000	2939.69.0000
2939.72.0000	2939.79.0000	2939.80.0010	2939.80.0050
2940.00.6000	2941.10.1000	2941.10.2000	2941.10.3000
2941.20.1000	2941.20.5000	2941.30.0000	2941.40.0000
2941.50.0000	2941.90.1010	2942.00.3500	2942.00.5000
3001.20.0000	3001.90.0110	3001.90.0150	3001.90.0165
3001.90.0195	3002.12.0010	3002.12.0020	3002.12.0030
3002.12.0090	3002.49.0010	3002.90.5210	3003.10.0000
3003.41.0000	3003.42.0000	3003.90.0160	3004.10.1020
3004.10.1045	3004.10.5048	3004.10.5049	3004.10.5055
3004.10.5065	3004.10.5075	3004.20.0020	3004.20.0030
3004.20.0045	3004.20.0055	3004.20.0065	3004.20.0070
3004.20.0071	3004.20.0072	3004.20.0076	3004.20.0080
3004.32.0010	3004.32.0040	3004.39.0020	3004.39.0030
3004.39.0040	3004.39.0045	3004.42.0000	3004.50.1000
3004.50.2000	3004.50.3000	3004.50.4000	3004.50.5010
3004.50.5020	3004.50.5030	3004.50.5040	3004.60.0000
3004.90.9203	3004.90.9204	3004.90.9205	3004.90.9207
3004.90.9209	3004.90.9212	3004.90.9213	3004.90.9217
3004.90.9218	3004.90.9219	3004.90.9220	3004.90.9222
3004.90.9223	3004.90.9224	3004.90.9226	3004.90.9227
3004.90.9228	3004.90.9229	3004.90.9230	3004.90.9232
3004.90.9233	3004.90.9234	3004.90.9235	3004.90.9237
3004.90.9238	3004.90.9239	3004.90.9240	3004.90.9241

3004.90.9242	3004.90.9244	3004.90.9245	3004.90.9247
3004.90.9248	3004.90.9250	3004.90.9254	3004.90.9255
3004.90.9256	3004.90.9257	3004.90.9258	3004.90.9261
3004.90.9262	3004.90.9264	3004.90.9265	3004.90.9266
3004.90.9269	3004.90.9272	3004.90.9274	3004.90.9275
3006.30.1000	3006.30.5000	3006.60.0000	3006.70.0000
3006.93.1000	3006.93.2000	3006.93.5000	3006.93.6000
3006.93.8000''			

[FR Doc. 2026–19498 Filed 9–21–26; 4:15 pm]

BILLING CODE 3510–33–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[RTID 0648–XG068]

New England Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meeting.

SUMMARY: The New England Fishery Management Council (Council) is holding a hybrid public meeting of its Scientific and Statistical Committee (SSC) to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). Recommendations from this group will be brought to the full Council for formal consideration and action, if appropriate.

DATES: This meeting will be held on Wednesday, October 7, 2026, beginning at 9 a.m. EDT. Webinar registration information: *https://nefmc-org.zoom.us/meeting/register/wjpr-MRURaOpmcuOPkoi0g.*

ADDRESSES: This meeting will take place at the Fairfield Inn & Suites/Waypoint Event Center, 185 MacArthur Drivet, New Bedford, MA 02740; phone: (774) 634–2000.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.

FOR FURTHER INFORMATION CONTACT: Cate O'Keefe, Executive Director, New England Fishery Management Council; telephone: (978) 465–0492.

SUPPLEMENTARY INFORMATION:

Agenda

The Scientific and Statistical Committee will meet to consider the information provided by the Council's Scallop and Groundfish Plan Development Teams, including stock assessment or data update information where appropriate; recommend the overfishing limits and acceptable biological catches for: Atlantic sea scallop for fishing years (FY) 2027 and 2028 (default); Northern windowpane flounder for FY 2027–2031; Southern windowpane flounder for FY 2027–2031; Witch flounder for FY 2027–2031. Other business will be discussed as necessary.

Although non-emergency issues not contained on the agenda may come before this Council for discussion, those issues may not be the subject of formal action during this meeting. Council action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency. The public also should be aware that the meeting will be recorded. Consistent with 16 U.S.C. 1852, a copy of the recording is available upon request.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Cate O'Keefe, (see **FOR FURTHER INFORMATION CONTACT**), at least 5 days prior to the meeting date.

(Authority: 16 U.S.C. 1801 *et seq.*)

Dated: September 21, 2026.

Rey Israel Marquez,

Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 2026–19452 Filed 9–22–26; 8:45 am]

BILLING CODE 3510–22–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2077–132]

Great River Hydro, LLC; Notice of Application for Temporary Variance Accepted for Filing, Soliciting Comments, Motions To Intervene, and Protests

Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:

a. *Application Type:* Non-capacity Amendment.

b. *Project No:* 2077–132.

c. *Date Filed:* September 10, 2026.

d. *Applicant:* Great River Hydro, LLC.

e. *Name of Project:* Fifteen Mile Hydroelectric Project.

f. *Location:* The project is located on the Connecticut River near the Town of Littleton in Grafton County, New Hampshire, and Caledonia County, Vermont.

g. *Filed Pursuant to:* Federal Power Act, 16 U.S.C. 791a–825r.

h. *Applicant Contact:* Jennifer Griffin, Great River Hydro, LLC, 2 Killeen Street, North Walpole, NH, 03609, *jgriffin@greatriverhydro.com,* (603) 445–6806.

i. *FERC Contact:* Kari Bradberry, (202) 502–8743, *Kari.Bradberry@ferc.gov.*

j. *Cooperating agencies:* With this notice, the Commission is inviting federal, state, local, and Tribal agencies with jurisdiction and/or special expertise with respect to environmental issues affected by the proposal, that wish to cooperate in the preparation of any environmental document, if applicable, to follow the instructions for filing such requests described in item k below. Cooperating agencies should note the Commission's policy that agencies that cooperate in the preparation of any environmental document cannot also intervene. *See* 94 FERC ¶ 61,076 (2001).

k. *Deadline for filing comments, motions to intervene, and protests:* October 19, 2026 5:00 p.m. Eastern Time.

The Commission strongly encourages electronic filing. Please file comments, motions to intervene, and protests using the Commission's eFiling system at *http://www.ferc.gov/docs-filing/efiling.asp.* Commenters can submit brief comments up to 6,000 characters, without prior registration, using the eComment system at *http://www.ferc.gov/docs-filing/ecomment.asp.* For assistance, please contact FERC Online Support at *FERCOnlineSupport@ferc.gov,* (866) 208–3676 (toll free), or (202) 502–8659 (TTY). In lieu of electronic filing, you may submit a paper copy. Submissions sent via the U.S. Postal Service must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory